A population-based cohort study found an association between bleeding events in Afib patients on oral anticoagulation and cancer diagnoses. In cases where cancer was diagnosed, it was more likely ...

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly elevates the risk of thromboembolic events, most notably ischaemic stroke. Anticoagulation therapy has long been a ...

Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...

At what platelet count can I safely initiate long-term anticoagulation with warfarin (Coumadin) in cancer patients with thrombocytopenia and persistent atrial fibrillation (AF)?—EDGAR C. SALIRE, NP-C, ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

A new study suggests that retrievable inferior vena cava filters do not further improve outcomes in patients with severe acute pulmonary embolism who receive anticoagulation therapy. Specifically, the ...

Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research ...

Please provide your email address to receive an email when new articles are posted on . Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents ...

In addition to receiving the award, Cadrenal was featured in the current edition of Pharma Tech Outlook. Entitled Pioneering Innovation in Anticoagulation for Rare Cardiovascular Conditions, the ...

Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, ...